immunotherapy

IRP’s Giorgio Trinchieri Elected to National Academy of Sciences

IRP Scientist Has Found New Ways to Wield the Immune System Against Cancer

Dr. Giorgio Trinchieri

Over the past twenty or so years, we’ve seen a sea change in many cancer therapies resulting from advances in immunotherapy. Rather than trying to poison cancer cells with chemotherapy or rip apart their DNA with radiation, these treatments help our own bodies attack the disease. As a result, we’ve seen a remarkable reduction in cancer deaths from many types of tumors. 

NIH Distinguished Investigator Giorgio Trinchieri, M.D., has long stood at the forefront of these discoveries. This year, he was elected to the National Academy of Sciences (NAS) for his achievements in identifying the mechanisms regulating the activity of certain classes of immune cells and how the environment around a tumor interacts with the immune system to suppress an immune response to the disease. This includes searching for ways to expand the benefits of immunotherapy to more patients.

Symposium Spotlights Promising Female Scientists

Annual Event Recognizes Three Young Researchers’ Scientific Accomplishments

Dr. Jennifer Zink

For decades, NIH has been working to solve the problems that have long stymied the careers of many young women interested in becoming scientists. As that essential effort continues, it’s important to shine a spotlight on some of the talented female researchers who are contributing to our knowledge of human health and biology right now.

One way the IRP does that is through the annual NIH Women Scientists Advisors (WSA) Scholar Award Symposium, which each year gives three early-career female scientists working in NIH labs the opportunity to present their work to the entire IRP community. At this year’s symposium, which took place April 29, the most recent group to be named WSA Scholars by NIH’s Women Scientists Advisors committee discussed their efforts to probe pollution’s impact on health, improve immunotherapy for cancer, and examine how screen time affects kids. Read on to learn more about their award-winning research.

Alternative Therapy Relieves Immunotherapy’s Neurological Consequences

Case Studies Highlight New Way to Treat Common Side Effect

child with cancer

New medical treatments nearly always come packaged with new side effects. CAR-T cell therapy, a game-changing ‘immunotherapy’ for cancer, is no exception. However, a set of case studies reported by IRP researchers could help physicians better contend with one of the therapy’s most worrisome complications.

CAR-T cell therapy involves collecting immune cells called T cells from a patient's blood, genetically modifying them to turn them into cancer killers, growing millions of the modified cells in the lab, and then returning the cancer-seeking missiles to the patient’s body. As promising as the approach is for eliminating cancer, the first CAR-T cell therapy was approved by the U.S. Food and Drug Administration (FDA) only a bit more than six years ago, so clinicians are still figuring out the best ways to manage its less desirable effects.

New Lasker Scholars Are Coming for Cancer

IRP Program Supports Cutting-Edge Cancer Research

Dr. Rosa Nguyen

The cumulative years of experience among the IRP’s large cadre of cancer researchers is truly astounding, with numerous scientists having spent half a century or more studying the disease at NIH. As incredibly valuable as their hard-earned wisdom is to finding new treatments for cancer, any scientific field also benefits tremendously from a constant influx of young talent. That’s where the IRP’s Lasker Clinical Research Scholars Program comes in.

The Lasker program identifies extremely promising early-career physician-scientists in a wide variety of fields and provides them with funding and resources to start their own independent labs at NIH. Over the past year, purely by coincidence, all of the Lasker Scholars selected happen to specialize in the study and treatment of cancer. Read on to learn more about the new ideas and bounding enthusiasm these fresh faces are bringing to NIH’s fight against the disease.

The Boon of Blood

A Look Inside NIH’s Department of Transfusion Medicine

a patient receiving blood during a surgery

The essential role of blood in our bodies has been recognized as far back as the time of ancient Greece, when the Greek physician Hippocrates included it in his list of four ‘humors’ that influence our health and emotions. Since then, scientists have vastly expanded our understanding of the dark red liquid running through our veins and arteries. Nowadays, researchers and technicians like those in NIH’s Department of Transfusion Medicine (DTM) can not only safely remove blood from one person and transfuse it into another, but they can also transform it into incredible forms of therapy.

The Life-Saving NIH Blood Bank

Blood Donors Play Critical Role in IRP’s Mission

Hal Wilkins (left) and Dr. Kamille West-Mitchell (right) pose with a sign for the NIH Blood Bank

The NIH IRP is full of vampires. Hundreds of patients at the NIH Clinical Center — not to mention scientists in roughly 200 IRP labs — depend on blood provided by NIH’s very own blood bank.

Conveniently located in the NIH Clinical Center, the NIH Blood Bank collects roughly 4,000 units of ‘whole blood’ each year — the process most people think of when they think of donating blood. It also receives more than 2,000 annual donations of specific blood components, which are collected via a process that separates them from other parts of the blood and returns the rest to the donor’s body. Most of those donations gather blood-clotting platelets, but the NIH Blood Bank also occasionally collects oxygen-carrying red blood cells and infection-fighting ‘convalescent plasma.’

IRP Research Yields Life-Changing Treatments

Highlighting Drugs and Vaccines Stemming from NIH Discoveries

syringe and vials of medicine

On May 3, more than six decades of IRP research culminated in the U.S. Food and Drug Administration (FDA) approving the world’s first vaccine for respiratory syncytial virus (RSV), a disease that puts tens of thousands of Americans in the hospital each year and kills thousands. While the new vaccine, called Arexy, has been getting all the headlines recently, it is only the latest example of a slew of FDA-approved medications and vaccines that might never have existed without the tireless efforts of scientists at NIH.

Indeed, a recently published study led by Mark Rohrbaugh, Ph.D., J.D., a special advisor in the NIH Office of Science Policy, found that inventions developed at NIH have contributed to more FDA-approved products than those created at any other nonprofit research institution in the world over the past five decades. NIH tops the study’s list with 27 FDA-approved products, six more than the study attributed to the combined efforts of all the schools in the University of California system.

Dying Tumor Cells Suppress Anti-Cancer Immune Response

IRP Study Points to Strategies to Stop Disease From Spreading

T cells (red) attacking cancer cell (white)

Ancient Greek myth describes how the hero Hercules battled the many-headed hydra, which regrew two heads every time Hercules cut one off. This frustrating fight against a seemingly invulnerable opponent would be an apt metaphor for treating cancer, in which tumor cells sometimes die in a particular way that actually helps their brethren multiply and spread to other parts of the body. In a study of that phenomenon using a mouse model of breast cancer, IRP researchers discovered that it occurs because that form of cell death suppresses the immune system’s response to the cancer, a finding that points to several potential ways to improve cancer therapy.

Creating Cutting-Edge Cancer Vaccines

IRP Research Identifies a Tantalizing Target for Cancer Immunotherapy

person getting vaccine injection

February 4 is World Cancer Day, a time to mark international efforts to prevent, detect, and treat cancer. Immunotherapy, one of the most significant advances in treating cancer, was pioneered here at NIH more than 30 years ago. Today, IRP senior investigator Claudia M. Palena, Ph.D., is pushing cancer immunotherapy forward with the discovery of a novel target for cancer vaccines.

Postdoc Profile: From Bench to Bedside and Back Again

Dr. Stefan Barisic Turns Laboratory Discoveries into Kidney Cancer Treatments

Dr. Stefan Barisic

The Laboratory of Transplantation Immunotherapy sits at the heart of the NIH Clinical Center, just down the hallway from the Southeast inpatient unit. Here, IRP postdoctoral research fellow Stefan Barisic, M.D., labors at the bench with the goal of creating practical treatments for kidney cancer patients. Having such proximity to his patients was one of the chief attractions of working at NIH for Dr. Barisic.

“The NIH Clinical Center is an amazing place because it has all the resources you need to go from the bench to the bedside and back to the bench all in one building,” says Dr. Barisic.